1.89
-0.19(-9.13%)
Currency In USD
| Previous Close | 2.08 |
| Open | 1.93 |
| Day High | 2.09 |
| Day Low | 1.89 |
| 52-Week High | 3.86 |
| 52-Week Low | 1.38 |
| Volume | 314,413 |
| Average Volume | 4.53M |
| Market Cap | 7.89M |
| PE | -0.67 |
| EPS | -2.84 |
| Moving Average 50 Days | 1.87 |
| Moving Average 200 Days | 2.39 |
| Change | -0.19 |
If you invested $1000 in STRATA Skin Sciences, Inc. (SSKN) 10 years ago, it would be worth $31.5 as of October 19, 2025 at a share price of $1.89. Whereas If you bought $1000 worth of STRATA Skin Sciences, Inc. (SSKN) shares 5 years ago, it would be worth $148.82 as of October 19, 2025 at a share price of $1.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
GlobeNewswire Inc.
Oct 14, 2025 12:15 PM GMT
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s XTRAC capability to address the condition HORSHAM, Pa
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
GlobeNewswire Inc.
Oct 03, 2025 2:50 PM GMT
HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing in
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
GlobeNewswire Inc.
Sep 30, 2025 12:15 PM GMT
HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of de